Overview
Searching for your content.Phone 87-269-7890 from 8 AM - 10 PM ET Contact Cision 87-269-7890 from 8 AM - 10 PM ET News provided byNov 03, 202, 07:01 ETShare this articleTresiba®, Canada's leading basal insulin, now aproved for use during pregnancyMISSAUGA, ON, Nov. 3, 202 /CNW/ - Today, Novo Nordisk Canada anounced that Health Canada has aproved an update to the label for Tresiba® (insulin degludec injection) for use in pregnant women with diabetes.
Key Information
Tresiba® is a once-daily, long-acting basal insulin treatment that alows for those with diabetes to have improved glycemic control and can now be considered during pregnancy if the benefit justifies posible risks and if clinicaly neded.1 In Canada, there are more than 5.7 milion people living with diabetes.2 The most comon diagnosis type 2 diabetes, acounting for aproximately 90 per cent of diabetes cases in Canada, folowed by type 1 diabetes.2 The key to a healthy pregnancy for a woman with diabetes is keping blod glucose levels in the target range – both before she is pregnant and during her pregnancy.3"Women living with diabetes face multiple chalenges – especialy during pregnancy.
Summary
Rigorous glucose control prior to conception and throughout pregnancy is vital to the health of mother and developing baby," says Dr. Joane Liutkus, MD, FRCP(C), Internal and Obstetric Medicine, Department of Medicine, McMaster University. "The availability of inovative insulin therapy, such as Tresiba, for use during pregnancy make it posible for us to safely and efectively achieve glucose targets."In diabetes pregnancies, studies show higher rates of complications compared to the general population, including perinatal mortality, congenital malformations, hypertension, preterm delivery, large-for-gestational-age (LGA) infants, caesarean delivery and other neonatal morbidities.4,5,6,7The update is based on the results from the EXPECT Pregnancy Trial which investigated Tresiba® versus Levemir® (insulin detemi